MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • 2016 International Congress

    Multiple system atrophy with motor fluctuations: A presynaptic disease variant?

    Y. Compta, S.C. Cerquera, N. Falgàs, E. Gelpí, V. Puente, A. Cámara, L. Planellas, M.J. Martí, F. Valldeoriola (Barcelona, Spain)

    Objective: To describe a case-series of Parkinsonian multiple system atrophy (MSAp) firstly diagnosed with Parkinson's disease (PD) due to clear-cut and severe l-dopa-induced motor fluctuations…
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

    E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)

    Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…
  • 2016 International Congress

    Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations

    C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

    Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…
  • 2016 International Congress

    Pulmonary dysfunction in Parkinson’s disease: A feature of early disease?

    G. Baille, T. Perez, D. Devos, L. Defebvre, C. Moreau (Lille, France)

    Objective: To characterize the abnormalities in pulmonary function tests (PFT) in early-diagnosed PD patients and to assess their prognostic features 2 years after. Background: Pulmonary…
  • 2016 International Congress

    Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease

    M. Tomiyama, Y. Funamizu, T. Kon, R. Haga, T. Ueno, H. Nishijima, A. Arai, C. Suzuki, J.I. Nunomura, M. Baba (Aomori, Japan)

    Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…
  • 2016 International Congress

    Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)

    F. Kerwood, C. Kenney, K. Kieburtz, W. Olanow, C. Resburg, J. Krishnaswami, S. Bandak (San Francisco, CA, USA)

    Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…
  • 2016 International Congress

    Treating Parkinson’s 2015–A nationwide survey of treatment responses and complications in 1000 Irish patients with Parkinson’s disease

    C. Stubbe, P. Bogdanova-Mihaylova, N. Kavanagh, K. Mulpeter, D. Bradley, T. Lynch, T. Counihan, P. Brown, S. O'Sullivan, R.A. Walsh (Dublin, Ireland)

    Objective: To collect real-life data from a large cohort with Parkinson's disease (PD), with particular emphasis on drug regimens, motor complications, and quality of life…
  • 2016 International Congress

    AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia

    L. Kadastik-Eerme, N. Taba, P. Taba (Tartu, Estonia)

    Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley